A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.

Simple item page
dc.contributor.authorWu, M D
dc.contributor.authorWang, Y
dc.contributor.authorDing, T
dc.contributor.authorZhou, Y F
dc.contributor.authorSong, J
dc.contributor.authorLiu, X H
dc.contributor.authorWei, M H
dc.contributor.authorYang, Q H
dc.contributor.authorZhou, J
dc.contributor.authorWang, S H
dc.contributor.authorLv, Q Y
dc.date.accessioned2015-06-23T11:08:52Z
dc.date.available2015-06-23T11:08:52Z
dc.date.issued2014-03
dc.description.abstractBACKGROUND: Bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A, was described to be effective in the treatment of recurrent or platinum‑resistance ovarian cancer. The present retrospective study was performed to further evaluate the clinical efficacy and toxicity of bevacizumab in the treatment of Chinese recurrent ovarian cancer patients who had been previously treated by platinum‑based chemotherapy. MATERIALS AND METHODS: We reviewed the hospital database and finally included 26 recurrent ovarian cancer patients who were treated with bevacizumab combined with gemcibabine or paclitaxel or single agent. All included patients received >3 cycle of bevacizumab treatment. The tumor response, overall survival, and toxicities were documented. RESULTS: Under the treatment of bevacizumab combined with gemcibabine or paclitaxel, 2 complete response (7.7%), 8 partial response (30.8%), 7 stable disease (26.9%) and 9 progression disease (34.6%) was documented with the objective response rate of 38.5% and disease control rate of 65.4%. The median overall survival from the first application of bevacizumab was 15.3 months [Figure 1] for all of the 26 patients. The median overall survival time was 16.2 and 14.0 months for bevacizumab + gemcitabine and bevacizumab + paclitaxel treatment schedule respectively. The overall survival was not different between bevacizumab + gemcitabine and bevacizumab + paclitaxel treatment regimen hazard ratio = 0.80 (95% confidence interval: 0.32–2, P = 0.64). The hypertension and proteinuria were the major bevacizumab related toxicities. CONCLUSIONS: Bevacizumab combined with gemcibabine or paclitaxel was a promising treatment schedule for platinum‑resistance recurrent ovarian cancer.en_US
dc.identifier.citationWu M D, Wang Y, Ding T, Zhou Y F, Song J, Liu X H, Wei M H, Yang Q H, Zhou J, Wang S H, Lv Q Y. A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer. Indian Journal of Cancer. 2014 Mar; 51(7_Suppl): s103-s105.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/158233
dc.language.isoenen_US
dc.source.urihttps://www.indianjcancer.com/article.asp?issn=0019-509X;year=2014;volume=51;issue=7;spage=103;epage=105;aulast=Wuen_US
dc.subjectBevacizumaben_US
dc.subjectefficacyen_US
dc.subjectgemcibabineen_US
dc.subjectpaclitaxelen_US
dc.subjectplatinum‑resistanceen_US
dc.subjectrecurrent ovarian canceren_US
dc.subjecttoxicityen_US
dc.titleA retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijc2014v51n7ps103.pdf
Size:
280.81 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Cancer